Meyka Pro banner
cbdMD, Inc.

cbdMD, Inc. Fundamental Analysis (AMEX: YCBD)

YCBD●AMEX
HealthcareDrug Manufacturers - Specialty & Generic
$0.39
$0.04(11.26%)
U.S. Market opens in 6h 8m

cbdMD, Inc. Fundamental Analysis (AMEX: YCBD)

cbdMD, Inc. (AMEX: YCBD) shows weak financial fundamentals with a PE ratio of -1.25, profit margin of -13.80%, and ROE of -34.25%. The company generates $0.0B in annual revenue with N/A year-over-year growth of N/A.

Key Strengths

Cash Position51.53%
PEG Ratio-0.01
Current Ratio2.50

Areas of Concern

ROE-34.25%
Operating Margin-13.87%
We analyze YCBD's fundamental strength across five key dimensions.

The stock receives a Fundamental Health Score of -132.2/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.

Fundamental Health Score

F
-132.2/100

We analyze YCBD's fundamental strength across five key dimensions:

Efficiency Score

Weak

YCBD struggles to generate sufficient returns from assets.

ROA > 10%
-21.97%

Valuation Score

Excellent

YCBD trades at attractive valuation levels.

PE < 25
-1.25
PEG Ratio < 2
-0.01

Growth Score

Weak

YCBD faces weak or negative growth trends.

Revenue Growth > 5%
N/A
EPS Growth > 10%
N/A

Financial Health Score

Excellent

YCBD maintains a strong and stable balance sheet.

Debt/Equity < 1
0.27
Current Ratio > 1
2.50

Profitability Score

Weak

YCBD struggles to sustain strong margins.

ROE > 15%
-3425.06%
Net Margin ≥ 15%
-13.80%
Positive Free Cash Flow
No

Key Financial Metrics

Is YCBD Expensive or Cheap?

P/E Ratio

YCBD trades at -1.25 times earnings. This suggests potential undervaluation.

-1.25

PEG Ratio

When adjusting for growth, YCBD's PEG of -0.01 indicates potential undervaluation.

-0.01

Price to Book

The market values cbdMD, Inc. at 0.49 times its book value. This may indicate undervaluation.

0.49

EV/EBITDA

Enterprise value stands at -3.55 times EBITDA. This is generally considered low.

-3.55

How Well Does YCBD Make Money?

Net Profit Margin

For every $100 in sales, cbdMD, Inc. keeps $-13.80 as profit after all expenses.

-13.80%

Operating Margin

Core operations generate -13.87 in profit for every $100 in revenue, before interest and taxes.

-13.87%

ROE

Management delivers $-34.25 in profit for every $100 of shareholder equity.

-34.25%

ROA

cbdMD, Inc. generates $-21.97 in profit for every $100 in assets, demonstrating efficient asset deployment.

-21.97%

Following the Money - Real Cash Generation

Operating Cash Flow

cbdMD, Inc. generates limited operating cash flow of $-468.54M, signaling weaker underlying cash strength.

$-468.54M

Free Cash Flow

cbdMD, Inc. generates weak or negative free cash flow of $-660.69M, restricting financial flexibility.

$-660.69M

FCF Per Share

Each share generates $-58.96 in free cash annually.

$-58.96

FCF Yield

YCBD converts -145.87% of its market value into free cash.

-145.87%

Financial Ratios Analysis

Valuation Ratios

P/E Ratio

Price to earnings ratio

-1.25

vs 25 benchmark

PEG Ratio

Price/earnings to growth ratio

-0.01

vs 25 benchmark

P/B Ratio

Price to book value ratio

0.49

vs 25 benchmark

P/S Ratio

Price to sales ratio

0.20

vs 25 benchmark

Financial Health

Debt/Equity

Total debt to shareholders' equity

0.27

vs 25 benchmark

Current Ratio

Current assets to current liabilities

2.50

vs 25 benchmark

Efficiency Ratios

ROE

Return on equity percentage

-0.34

vs 25 benchmark

ROA

Return on assets percentage

-0.22

vs 25 benchmark

ROCE

Return on capital employed

-0.29

vs 25 benchmark

How YCBD Stacks Against Its Sector Peers

MetricYCBD ValueSector AveragePerformance
P/E Ratio-1.2531.25 Better (Cheaper)
ROE-34.25%563.00% Weak
Net Margin-13.80%7024.00% Weak
Debt/Equity0.270.51 Strong (Low Leverage)
Current Ratio2.505.76 Strong Liquidity
ROA-21.97%-63.00% (disorted) Weak

YCBD outperforms its industry in 3 out of 6 key metrics, but lagging in ROE.

Historical Growth Performance

5-Year Growth Trajectory

This section reviews cbdMD, Inc.'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.

Revenue CAGR

N/A

Industry Style: Defensive, Growth, Innovation

EPS CAGR

N/A

Industry Style: Defensive, Growth, Innovation

FCF CAGR

N/A

Industry Style: Defensive, Growth, Innovation

Fundamental Analysis FAQ